{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=58&state=Florida",
    "query": {
      "state": "Florida",
      "city": "Orlando",
      "page": 58
    },
    "page_size": 10
  },
  "pagination": {
    "page": 58,
    "page_size": 10,
    "total_count": 6864,
    "total_pages": 687,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=59&state=Florida&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=57&state=Florida&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T17:36:00.403Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03695380",
      "title": "A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "OVARIAN CANCER"
      ],
      "interventions": [
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 77,
      "start_date": "2019-01-09",
      "completion_date": "2023-07-12",
      "has_results": false,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-11-09T17:36:00.403Z",
      "location_count": 9,
      "location_summary": "Tucson, Arizona • La Jolla, California • Jacksonville, Florida + 6 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03695380"
    },
    {
      "nct_id": "NCT00486668",
      "title": "A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Invasive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NSABP Foundation Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 529,
      "start_date": "2007-07",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2016-06-06",
      "last_synced_at": "2026-11-09T17:36:00.403Z",
      "location_count": 103,
      "location_summary": "Mobile, Alabama • La Jolla, California • Long Beach, California + 88 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00486668"
    },
    {
      "nct_id": "NCT06096779",
      "title": "A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-07-15",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-09T17:36:00.403Z",
      "location_count": 53,
      "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 38 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06096779"
    },
    {
      "nct_id": "NCT06457997",
      "title": "A Study of PHN-010 in Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Colon Cancer",
        "Endometrial Cancer",
        "Ovarian Cancer",
        "Cervical Cancer",
        "Advanced Solid Tumor",
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "PHN-010",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pheon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2024-07-01",
      "completion_date": "2025-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-11-09T17:36:00.403Z",
      "location_count": 8,
      "location_summary": "Orlando, Florida • Boston, Massachusetts • New York, New York + 5 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06457997"
    },
    {
      "nct_id": "NCT06178991",
      "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Influenza and COVID-19 Combination A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Licensed influenza vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza and COVID-19 Combination B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 8795,
      "start_date": "2023-12-20",
      "completion_date": "2024-11-26",
      "has_results": true,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-11-09T17:36:00.403Z",
      "location_count": 106,
      "location_summary": "Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06178991"
    },
    {
      "nct_id": "NCT07227597",
      "title": "A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer Extensive Stage"
      ],
      "interventions": [
        {
          "name": "Gocatamig",
          "type": "DRUG"
        },
        {
          "name": "I-DXd",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Rescue Medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2026-01-29",
      "completion_date": "2030-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-09T17:36:00.403Z",
      "location_count": 13,
      "location_summary": "Santa Rosa, California • Aurora, Colorado • Orlando, Florida + 10 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227597"
    },
    {
      "nct_id": "NCT05092360",
      "title": "Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Platinum-resistant Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Nemvaleukin and Pembrolizumab Combination",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nemvaleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin (PLD)",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Topotecan",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mural Oncology, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 456,
      "start_date": "2022-01-10",
      "completion_date": "2025-05-08",
      "has_results": true,
      "last_update_posted_date": "2025-08-28",
      "last_synced_at": "2026-11-09T17:36:00.403Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05092360"
    },
    {
      "nct_id": "NCT03595618",
      "title": "A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "GLPG1972",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lakefront Biotherapeutics NV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 932,
      "start_date": "2018-08-14",
      "completion_date": "2020-07-14",
      "has_results": true,
      "last_update_posted_date": "2021-07-28",
      "last_synced_at": "2026-11-09T17:36:00.403Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03595618"
    },
    {
      "nct_id": "NCT02851797",
      "title": "Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "givinostat",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Italfarmaco",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "MALE",
        "summary": "6 Years to 17 Years · Male only"
      },
      "enrollment_count": 179,
      "start_date": "2017-06-06",
      "completion_date": "2022-02-22",
      "has_results": true,
      "last_update_posted_date": "2023-02-02",
      "last_synced_at": "2026-11-09T17:36:00.403Z",
      "location_count": 13,
      "location_summary": "Davis, California • San Diego, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02851797"
    },
    {
      "nct_id": "NCT06190691",
      "title": "Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Hepatic Insufficiency"
      ],
      "interventions": [
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 36,
      "start_date": "2020-12-18",
      "completion_date": "2021-12-30",
      "has_results": true,
      "last_update_posted_date": "2025-01-09",
      "last_synced_at": "2026-11-09T17:36:00.403Z",
      "location_count": 8,
      "location_summary": "Anaheim, California • Tustin, California • Edgewater, Florida + 3 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Edgewater",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06190691"
    }
  ]
}